Scroll Back to Top

28–30 June 2022

Precision Medicine World Conference (PMWC)

In-person

Silicon Valley Convention Center
Santa Clara, CA

Register

19–20 May 2022

Personalized Medicine Conference

In-person

Ritz Carlton Laguna Niguel
Dana Point, CA

Register

3–7 June 2022

American Society of Clinical Oncology (ASCO) Annual Meeting 2022

In-Person and Online

McCormick Place
Chicago, IL

Abstracts at ASCO

Register

8–13 April 2022

American Association for Cancer Research (AACR) Annual Meeting 2022

Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes

Ernest N. Morial Convention Center
New Orleans, Louisiana

Register

2–4 March 2022

Association of Community Cancer Centers (ACCC) 48th Annual Meeting & Cancer Business Summit

Hybrid | In-Person and Live-Streaming

Washington, DC

Register
<span>Labcorp strengthens oncology leadership position with the addition of Personal Genome Diagnostics, a provider of comprehensive liquid biopsy and tissue-based genomic products and services</span>
December 23, 2021

Labcorp strengthens oncology leadership position with the addition of Personal Genome Diagnostics, a provider of comprehensive liquid biopsy and tissue-based genomic products and services

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 23, 2021-- Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.
Publication
Jeffrey M. Conroy, Sarabjot Pabla, Sean T. Glenn, R. J. Seager, Erik Van Roey, Shuang Gao, Blake Burgher, Jonathan Andreas, Vincent Giamo, Melissa Mallon, Yong Hee Lee, Paul DePietro, Mary Nesline6, Yirong Wang, Felicia L. Lenzo, Roger Klein, Shengle Zhang